Core Viewpoint - Recent developments for Lifan Pharmaceutical (stock code: 003020) focus on product procurement progress and market performance, with three core products expected to enhance sales and market share through national procurement [1] Group 1: Recent Events - Product Procurement Selection: On February 10, 2026, Lifan Pharmaceutical announced that its three products—Nifedipine Controlled-Release Tablets, Venlafaxine Hydrochloride Sustained-Release Tablets, and Trimethoprim Sustained-Release Tablets—are proposed for selection in the national procurement program, which could significantly boost sales and market share [2] - New Drug Application Progress: On the same day, the application for the raw material drug Finerenone was accepted by the National Medical Products Administration, aimed at treating chronic kidney disease related to type 2 diabetes, currently under review [2] Group 2: Stock Performance - Stock Price Movement: Over the past week (February 5 to 11), the stock price fluctuated by 0.84%, with a high of 26.99 yuan on February 6 and a low of 26.22 yuan on February 9. The closing price on February 11 was 26.53 yuan, with a single-day increase of 0.53% and a trading volume of 30.08 million yuan [3] - Capital Flow Situation: On February 11, there was a net outflow of 1.7835 million yuan from institutional investors, while retail investors showed a net inflow, indicating overall stable liquidity [3] Group 3: Sector Performance - Sector Comparison: During the same period, the pharmaceutical and biotechnology sector declined by 0.50%, while Lifan Pharmaceutical's stock performance was slightly better than the sector average [4] Group 4: Institutional Insights - Strategic Transformation Analysis: On February 6, 2026, Morningstar Research noted that Lifan Pharmaceutical is focusing on high-barrier areas such as osmotic pump controlled-release technology and narcotic drugs, with core products like Methylphenidate Hydrochloride Sustained-Release Tablets already on the market. However, short-term performance may experience fluctuations, necessitating attention to new drug volume and balancing R&D investments [5]

Core Viewpoint - The company has received a notice of acceptance for the raw material drug Fenofibrate from the National Medical Products Administration, indicating that the product has entered the registration review stage [1] Group 1 - The acceptance of the raw material drug application signifies that the product is now in the registration review phase [1] - The approval of Fenofibrate would further enrich the company's raw material drug product pipeline [1] - The impact on the company's recent performance is not expected to be significant [1]

立方制药（003020）(003020.SZ)公告，公司收到国家药品监督管理局下发的非奈利酮原料药上市申请 《受理通知书》。非奈利酮是一种新型、非甾体类、选择性盐皮质激素受体拮抗剂(MRA)，其制剂用于 与2型糖尿病相关的慢性肾病成人患者，可降低eGFR持续下降、终末期肾病的风险。 ...

智通财经APP讯，立方制药(003020.SZ)公告，公司收到国家药品监督管理局下发的非奈利酮原料药上市 申请《受理通知书》。非奈利酮是一种新型、非甾体类、选择性盐皮质激素受体拮抗剂(MRA)，其制剂 用于与2型糖尿病相关的慢性肾病成人患者，可降低eGFR持续下降、终末期肾病的风险。 ...

非奈利酮是一种新型、非甾体类、选择性盐皮质激素受体拮抗剂(MRA)，其制剂用于与2型糖尿病相关 的慢性肾病成人患者(肾小球滤过率估计值[eGFR]≥25至75ml/min/1.73m2，伴白蛋白尿)，可降低eGFR持 续下降、终末期肾病的风险。本次申请属于仿制境内已上市药品所用的化学原料药。截至本公告日，该 品种原料药登记备案的企业中，有5家登记状态为"A"(已批准在上市制剂使用的原料)，其余均为"I"(尚 未通过与制剂共同审评审批的原料)。 格隆汇2月10日丨立方制药(003020.SZ)公布，近日，公司收到国家药品监督管理局下发的非奈利酮原料 药上市申请《受理通知书》。 ...